| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief R&D Officer
1 company
Zalevsky Jonathan is a Chief R&D Officer at NEKTAR THERAPEUTICS. Recent SEC Form 4 filings include 0 buys and 10 sells.
Estimated insider holdings value: $2.1M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 20, 2024 | NKTR Nektar Therapeutics | Chief R&D Officer | Sell | 9,014 | $0.68 | $6,129.52 | -3.3% | +163.7% | +50.7% | |
| Nov 17, 2023 | NKTR Nektar Therapeutics | Chief R&D Officer | Sell | 9,646 | $0.49 | $4,726.54 | -3.4% | +53.7% | +122.2% | |
| Aug 16, 2023 | NKTR Nektar Therapeutics | Chief R&D Officer | Sell | 9,703 | $0.78 | $7,568.34 | -3.3% | -33.6% | +54.9% | |
| May 16, 2023 | NKTR Nektar Therapeutics | Chief R&D Officer | Sell | 9,791 | $0.72 | $7,049.52 | -3.2% | +15.2% | +155.9% | |
| Feb 16, 2023 | NKTR Nektar Therapeutics | Chief R&D Officer | Sell | 10,484 | $3.00 | $31,452.00 | -3.3% | -76.5% | -76.1% | |
| Nov 16, 2022 | NKTR Nektar Therapeutics | Chief R&D Officer | Sell | 13,460 | $3.57 | $48,052.20 | -4.1% | -14.2% | -85.7% | |
| Aug 18, 2022 | NKTR Nektar Therapeutics | Chief R&D Officer | Sell | 73,716 | $4.65 | $342,779.40 | -18.4% | -24.8% | -84.4% | |
| Aug 16, 2022 | NKTR Nektar Therapeutics | Chief R&D Officer | Sell | 10,560 | $4.76 | $50,265.60 | -2.6% | -12.8% | -83.6% | |
| May 16, 2022 | NKTR Nektar Therapeutics | Chief R&D Officer | Sell | 21,673 | $3.95 | $85,608.35 | -7.3% | +26.5% | -81.6% | |
| Feb 16, 2022 | NKTR Nektar Therapeutics | Chief R&D Officer | Sell | 10,912 | $10.95 | $119,486.40 | -3.8% | -64.8% | -73.4% |